Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

PhytoHealth Corp receives NDA approval for PG2 Injection 500 mg

Wednesday, 30 Apr 2014 02:06am EDT 

PhytoHealth Corp:Received NDA approval for PG2 Injection 500 mg from Ministry of Health and Welfare.PG2 Injection 500 mg is drug to reduce fatigue caused by cancer.Trial phase two of PG2 Injection 500 mg to cure idiopathic thrombocytopenic purpura has been finished.Trial phase two result of its bone drug to prevent osteoporosis of postmenopausal women is positive.Trial of its drug for faint to has finished. 

Company Quote

-0.2 -0.61%
21 Nov 2014